Premium
In vitro activities of new and conventional antimycotics against fluconazole‐susceptible and non‐susceptible Brazilian Candida spp. isolates
Author(s) -
Alves S. H.,
Da Matta D. A.,
Azevedo A. C.,
Loreto E. S.,
Boff E.,
Santurio J. M.,
Guarro J.
Publication year - 2006
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2006.01226.x
Subject(s) - fluconazole , flucytosine , itraconazole , microbiology and biotechnology , amphotericin b , biology , azole , candida albicans , candida dubliniensis , yeast , fungi imperfecti , in vitro , antifungal , corpus albicans , genetics
Summary The substantial increase in the rate of azole resistant Candida spp. yeast infections has become a serious treatment problem requiring new and more active antifungal agents. In this study, the in vitro activities of ravuconazole and albaconazole were compared with those of amphotericin B, flucytosine, itraconazole and fluconazole against 162 Brazilian isolates of Candida spp. from which 48 isolates had previously shown lower susceptibility or resistance to fluconazole. Ravuconazole susceptibility ranged from 84.6% ( Candida albicans ) to 100% for other species and albaconazole MIC 90 was ≤1.0 μ g ml −1 for all the species emphasising the potent activity of these triazoles. To our knowledge this is the first study evaluating the susceptibility of C. dubliniensis to albaconazole.